To end tuberculosis epidemic needs strengthen the management of screening and preventive treatment of latent tuberculosis infection in high-risk groups

doi:10.19982/j.issn.1000-6621.20220008

Chinese Journal of Antituberculosis ›› 2022, Vol. 44 ›› Issue (3): 209-214.doi: 10.19982/j.issn.1000-6621.20220008

• Expert Note • Previous Articles Next Articles

To end tuberculosis epidemic needs strengthen the management of screening and preventive treatment of latent tuberculosis infection in high-risk groups

MA Yan¹, LU Wei², GAO Lei³, CHU Nai-hui⁴, ZHOU Lin⁵, CHENG Shi-ming⁶()

¹Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China
²Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China
³Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730,China
⁴Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute,Beijing 101149, China
⁵Department of Patient Care, National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
⁶Chinese Antituberculosis Association, Beijing 100710, China

Received:2022-01-20 Online:2022-03-10 Published:2022-03-08
Contact: CHENG Shi-ming E-mail:smcheng@163.com
Supported by:
Major National Science and Technology Projects in the 12th Five Year Plan(2014ZX10003002-004);Major National Science and Technology Projects in the 12th Five Year Plan(2015ZX09108-003);Major National Science and Technology Projects in the 13th Five Year Plan(2018ZX10731301);Major National Science and Technology Projects in the 13th Five Year Plan(2020ZX09201001-005);Major National Science and Technology Projects in the 13th Five Year Plan(2018ZX10103001-001-008);Major National Science and Technology Projects in the 13th Five Year Plan(2017ZX10201301-001-003);Major National Science and Technology Projects in the 13th Five Year Plan(2017ZX09304009)

Abstract

Abstract:

Currently, the slow decline of tuberculosis incidence rate becomes a huge challenge to the goal of ending tuberculosis. In 2020, the estimated global latent tuberculosis infection (LTBI) population was nearly 2 billion. With the condition of no preventive intervention, 5% to 10% of them will develop into active tuberculosis in the lifetime, and the incidence rate is higher in high-risk population. The World Health Organization has called for the promotion of the prevention of LTBI worldwide, so as to achieve the goal of a rapid decline in the incidence rate of tuberculosis. This paper reviews the current situation of LTBI epidemic and preventive treatment, the incidence risk of high-risk population, screening methods, intervention and management suggestions, etc., in order to provide reference for formulating LTBI intervention and management strategies and measures in China.

Key words: Mycobacterium tuberculosis, Infectious disease incubation period, Diagnosis, Protective agents

CLC Number:

R52
R184.6

MA Yan, LU Wei, GAO Lei, CHU Nai-hui, ZHOU Lin, CHENG Shi-ming. To end tuberculosis epidemic needs strengthen the management of screening and preventive treatment of latent tuberculosis infection in high-risk groups[J]. Chinese Journal of Antituberculosis, 2022, 44(3): 209-214. doi: 10.19982/j.issn.1000-6621.20220008

References 24

[1]	Hartman-Adams H, Clark K, Juckett G. Update on latent tuberculosis infection. Am Fam Physician, 2014, 89(11):889-896. pmid: 25077395
[2]	World Health Organization. Global tuberculosis report 2015. Geneva: World Health Organization, 2015.
[3]	World Health Organization. Global tuberculosis report 2021. Geneva: World Health Organization, 2021.
[4]	中国医学科学院病原生物学研究所, 中国疾病预防控制中心, 中国科学院地理科学与资源研究所. 全国结核分枝杆菌潜伏感染率估算专家共识. 中国防痨杂志, 2022, 44(1):4-8. doi: 10.19982/j.issn.1000-6621.20210662. doi: 10.19982/j.issn.1000-6621.20210662
[5]	Oxlade O, Benedetti A, Adjobimey M, et al. Effectiveness and cost-effectiveness of a health systems intervention for latent tuberculosis infection management (ACT4): a cluster-randomised trial. Lancet Public Health, 2021, 6(5):e272-e282. doi: 10.1016/S2468-2667(20)30261-9. doi: 10.1016/S2468-2667(20)30261-9 URL
[6]	World Health Organization. WHO consolidated guidelines on tuberculosis Module 2: screening-systematic screening for tuberculosis disease. Geneva: World Health Organization, 2020.
[7]	Stagg HR, Zenner D, Harris RJ, et al. Treatment of latent tuberculosis infection: a network meta-analysis. Ann Intern Med, 2014, 161(6):419-428. doi: 10.7326/M14-1019. doi: 10.7326/M14-1019 URL
[8]	World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: World Health Organization, 2018.
[9]	World Health Organization. WHO consolidated guidelines on tuberculosis: module 1: prevention: tuberculosis preventive treatment. Geneva: World Health Organization, 2020.
[10]	中华人民共和国国家卫生健康委员会办公厅. 国家卫生健康委办公厅关于印发中国结核病预防控制工作技术规范(2020年版)的通知.国卫办疾控函〔2020〕279号. 2020-04-02.
[11]	World Health Organization. WHO guidelines on tuberculosis infection prevention and control: 2019 update. Geneva: World Health Organization, 2019.
[12]	Martinez L, Cords O, Horsburgh CR, et al. The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis. Lancet, 2020, 395(10228):973-984. doi: 10.1016/S0140-6736(20)30166-5. doi: 10.1016/S0140-6736(20)30166-5 URL
[13]	洪可, 张定宇, 阮连国. 武汉市HIV/AIDS患者潜伏性结核感染筛查及预防效果. 传染病信息, 2021, 34(5):422-425. doi: 10.3969/j.issn.1007-8134.2021.05.008. doi: 10.3969/j.issn.1007-8134.2021.05.008
[14]	梁瑞英, 徐伟, 吴春萍. 北京市朝阳区2013—2015年高校新生结核菌潜伏感染现状及发病情况. 中国学校卫生, 2019, 40(9):1373-1375,1379. doi: 10.16835/j.cnki.1000-9817.2019.09.026. doi: 10.16835/j.cnki.1000-9817.2019.09.026
[15]	郭倩文, 朱晓敏, 朱芳, 等. 接尘作业工人尘肺患者结核潜伏性感染的患病情况及影响因素分析. 实用预防医学, 2020, 27(9):1122-1124. doi: 10.3969/j.issn.1006-3110.2020.09.027. doi: 10.3969/j.issn.1006-3110.2020.09.027
[16]	Sepehri N, Saghanezhad SM, Khoddami F, et al. Meta-analysis of latent tuberculosis in healthcare workers in Iran: a retrospective review. Trans R Soc Trop Med Hyg, 2021, 115(9):965-974. doi: 10.1093/trstmh/trab006. doi: 10.1093/trstmh/trab006 URL
[17]	张霞, 汤泓. 上海市长宁区老年糖尿病患者结核潜伏感染现况和预防性治疗态度. 中国热带医学, 2021, 21(5):408-412. doi: 10.13604/j.cnki.46-1064/r.2021.05.03. doi: 10.13604/j.cnki.46-1064/r.2021.05.03
[18]	Basera TJ, Ncayiyana J, Engel ME. Prevalence and risk factors of latent tuberculosis infection in Africa: a systematic review and meta-analysis protocol. BMJ Open, 2017, 7(7):e012636. doi: 10.1136/bmjopen-2016-012636. doi: 10.1136/bmjopen-2016-012636 URL
[19]	卢水华, 陆伟. 新型结核菌素皮肤试验使用手册. 北京: 人民卫生出版社, 2021.
[20]	中国防痨协会. 高危人群结核分枝杆菌潜伏感染检测及预防性治疗专家共识. 中国防痨杂志, 2021, 43(9):874-878. doi: 10.3969/j.issn.1000-6621.2021.09.004. doi: 10.3969/j.issn.1000-6621.2021.09.004
[21]	中国防痨协会, 中国防痨协会学校与儿童结核病防治专业分会, 《中国防痨杂志》编辑委员会. 重组结核杆菌融合蛋白(EC)临床应用专家共识. 中国防痨杂志, 2020, 42(8):761-768. doi: 10.3969/j.issn.1000-6621.2020.08.001. doi: 10.3969/j.issn.1000-6621.2020.08.001
[22]	祁雪, 田建岭, 孙琳, 等. 儿童结核分枝杆菌潜伏感染的筛查和预防性治疗. 中国防痨杂志, 2018, 40(5):447-454. doi: 10.3969/j.issn.1000-6621.2018.05.003. doi: 10.3969/j.issn.1000-6621.2018.05.003
[23]	刘惠, 闻颖. 艾滋病患者和HIV感染者中结核潜伏性感染的诊断与预防性治疗. 中国防痨杂志, 2016, 38(1):57-60. doi: 10.3969/j.issn.1000-6621.2016.01.013. doi: 10.3969/j.issn.1000-6621.2016.01.013
[24]	舒薇, 孙玙贤, 张立杰, 等. 结核病的研究与创新——2021年世界卫生组织全球结核病报告解读. 中国防痨杂志, 2022, 44(1):45-48. doi: 10.19982/j.issn.1000-6621.20210685. doi: 10.19982/j.issn.1000-6621.20210685

To end tuberculosis epidemic needs strengthen the management of screening and preventive treatment of latent tuberculosis infection in high-risk groups

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 24

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	LI Dong-shuo, WANG Bin, LU Yu, XU Jian. Study of expression and function of Mycobacterium tuberculosis membrane protein MmpL5-MmpS5 [J]. Chinese Journal of Antituberculosis, 2022, 44(3): 227-233.
[2]	CHEN Meng-meng, DONG Jing, SUN Qi, HUANG Mai-ling, DING Ze-yu, SHI Yu-ting, JIA Hong-yan, DU Bo-ping, WEI Rong-rong, XING Ai-ying, ZHANG Zong-de, PAN Li-ping. Diagnostic performance of differentially expressed miRNA identified by gene chip in discriminating tuberculous meningitis from viral meningitis [J]. Chinese Journal of Antituberculosis, 2022, 44(3): 264-272.
[3]	YANG Cheng-qing, MEI Chun-lin, DU Rong-hui, LEI Mei, QIN Li-xin. Analysis of diagnosis and treatment for a pulmonary lymphangitic carcinomatosis misdiagnosed as pulmonary tuberculosis caused by false positive molecular biological test [J]. Chinese Journal of Antituberculosis, 2022, 44(3): 289-293.
[4]	FAN Ru, LI Xiao-fei. Research progress of molecular biology detection technology for tuberculosis [J]. Chinese Journal of Antituberculosis, 2022, 44(3): 294-298.
[5]	SUN Zhao-gang. Attention should be paid to the research and development of Mycobacterium tuberculosis antigen detection technology [J]. Chinese Journal of Antituberculosis, 2022, 44(2): 120-124.
[6]	WANG Shao-hua, ZHAO Guo-lian, WANG Pei, TAN Xiao-wen, CUI Xiao-li, KANG Lei, DANG Li-yun. Analysis of inconsistency between genotypic and phenotypic results of Mycobacterium tuberculosis rifampicin susceptibility test [J]. Chinese Journal of Antituberculosis, 2022, 44(2): 169-173.
[7]	ZHANG Can-you, CHEN Hui, FA Li-feng, ZHANG Hui, CHENG Jun. Evaluation of the effects of tuberculosis infection control training courses in China, 2016-2019 [J]. Chinese Journal of Antituberculosis, 2022, 44(2): 174-180.
[8]	ZHOU Ting-ting, ZHENG Xiao-man, OUYANG Jing, LU Yan-qiu, CHEN Yao-kai. Research progress on genes and mechanism of Mycobacterium tuberculosis resistance to pyrazinamide [J]. Chinese Journal of Antituberculosis, 2022, 44(1): 102-105.
[9]	Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College , Chinese Center for Disease Control and Prevention , Union Medical Institute of Geographic Sciences and Natural Resources Research, Chinese Academy of Sciences . Expert consensus on the estimation of the national burden on latent tuberculosis infection [J]. Chinese Journal of Antituberculosis, 2022, 44(1): 4-8.
[10]	GAO Lei, ZHANG Hui, HU Mao-gui, XU Cheng-dong, XIA Yin-yin, LI Tao, CHEN Wei, HE Yi-jun, CAO Xue-fang, XIN He-nan, ZHANG Hao-ran, ZHAO Yan-lin, WANG Jin-feng, CHENG Shi-ming, JIN Qi, LIU Jian-jun. Estimation of the national burden on latent tuberculosis infection based a multi-center epidemiological survey and the space statistics model [J]. Chinese Journal of Antituberculosis, 2022, 44(1): 54-59.
[11]	XU Yin-juan, ZHAO Guo-lian, CUI Xiao-li, WANG Pei, TAN Xiao-wen, YANG Shan-shan, WU Hao.. Evaluation of the effect of a new domestic improved Middlebrook liquid culture reagent on the culture of Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2022, 44(1): 60-63.
[12]	WU Jian, HOU Dai-lun. Application of deep learning in pulmonary tuberculosis imaging diagnosis [J]. Chinese Journal of Antituberculosis, 2022, 44(1): 91-94.
[13]	Chinese Antituberculosis Association. Expert consensus on detection and preventive treatment of latent tuberculosis infection in high-risk population [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 874-878.
[14]	ZHAO Xiu-juan, MO Jing-lian, SUN Tao, LIU Lin, ZHONG Ye-teng, PEI Hua, XIA Qian-feng. Prevalence and correlated factors of drug-resistant pulmonary tuberculosis admitted to the designated medical institutions in Hainan Province from 2015 to 2019 [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 916-923.
[15]	LIN Jian, LIN Shu-fang, DAI Zhi-song, ZHAO Yong, ZHOU Yin-fa, ZHANG Tian-lin, WEI Shu-zhen. Analysis of the drug resistance surveillance results of Mycobacterium tuberculosis in Fujian Province from 2016 to 2019 [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 924-928.